SynthesisCerebellum (London, England)2026
Infection-associated Opsoclonus: A Systematic Review.
Synthesis in Cerebellum (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opsoclonus is a chaotic, multidirectional eye movement characterized by rapid saccades. We aimed to systematically review infection-associated opsoclonus to define its pathogen spectrum, clinical features, treatments, and outcomes. PRISMA 2020 compliant review, PROSPERO registered (CRD420251161567). PubMed, Embase, Scopus and Google Scholar were searched. All search results were imported into EndNote 21 for deduplication. Two reviewers independently conducted screening and data extraction. Quality was assessed by Murad et al. and Newcastle–Ottawa Scales. In this analysis of 210 published cases of opsoclonus, the mean age was 35 years, with Asia contributing 43% of reports and India being the most frequent reporting country. Most patients were immunocompetent or presumed immunocompetent (78%). Viral infections predominated (63%), led by Severe Acute Respiratory Syndrome Coronavirus 2 (30%), followed by scrub typhus, Human Immunodeficiency Virus, West Nile virus, Borrelia, Epstein–Barr virus, Mycoplasma pneumoniae, and dengue virus. Latency was short, with 62% presenting within two weeks, supporting a para-infectious immune mechanism. Cerebrospinal fluid was normal in 43% and magnetic resonance imaging in 67%, indicating that normal investigations should not delay treatment. Management was mainly immunotherapy-based, with corticosteroids alone (40%) or combined with intravenous immunoglobulin (24%). Outcomes were favourable, with 43% recovering within one week and 41% within eight weeks. Immune mediation was inferred in 78%, a pattern consistently reproduced across sixteen cohort studies. Infection-associated opsoclonus is a treatable neurological syndrome arising from a broad infectious spectrum, predominantly viral. Early diagnosis and prompt immunotherapy are associated with rapid clinical improvement.
Indexed as
Identifiers
41661491What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.